Endocrinology

Catch up with FDA decisions, key trial results, podcast updates, and more.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

The long-acting growth hormone is now indicated for children aged 2.5 years and older with Idiopathic Short Stature, born Small for Gestational Age, or Noonan Syndrome.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Lilly’s groundbreaking new Zepbound administration option.

The list price of all 3 semaglutide drugs will be lowered to $675, marking a reduction of roughly 50% and 35% for Wegovy and Ozempic, respectively.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal Pump's recent Breakthrough Designation from the FDA.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of the Eversense 365 by Sequel Medtech and Senseonics, paired with the Twiist insulin pump.

The phase 3 REDEFINE 4 trial saw CagriSema achieve 23% weight loss, but fail to demonstrate noninferiority to tirzepatide in patients with overweight or obesity.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of Eli Lilly's Zepbound as an injectable with the KwikPen.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal implanted insulin pump, which has received Breakthrough Device designation from the FDA.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the controversy surrounding Hims and Hers and the risks of compounding GLP-1 formulas.

Stay updated with the latest healthcare breakthroughs, FDA actions and new phase 2 and 3 data, in this week’s essential news roundup.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Ozempic’s approval in a higher-dose oral form and lingering concerns over compounded drugs.

The data represent the highest and most significant improvement in AHV and the first statistically significant improvement in body proportionality in achondroplasia.

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

These data from the ongoing VESPER-3 phase 2b study highlight PF’3944’s capacity for reducing weight across 4 weekly-monthly dosing arms.

Catch up with major trial results, key FDA approvals, and more.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

The US Centers for Medicare & Medicaid Services selected 15 high-cost drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first-ever Part B drugs.